SG11201803382XA - Cgrp receptor antagonists - Google Patents

Cgrp receptor antagonists

Info

Publication number
SG11201803382XA
SG11201803382XA SG11201803382XA SG11201803382XA SG11201803382XA SG 11201803382X A SG11201803382X A SG 11201803382XA SG 11201803382X A SG11201803382X A SG 11201803382XA SG 11201803382X A SG11201803382X A SG 11201803382XA SG 11201803382X A SG11201803382X A SG 11201803382XA
Authority
SG
Singapore
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
antagonists
receptor
Prior art date
Application number
SG11201803382XA
Other languages
English (en)
Inventor
John Andrew Christopher
Miles Stuart Congreve
Sarah Joanne Bucknell
Francesca Deflorian
Mark Pickworth
Jonathan Stephen Mason
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of SG11201803382XA publication Critical patent/SG11201803382XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201803382XA 2015-10-30 2016-10-28 Cgrp receptor antagonists SG11201803382XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1519194.3A GB201519194D0 (en) 2015-10-30 2015-10-30 CGRP receptor antagonists
PCT/IB2016/056519 WO2017072723A1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
SG11201803382XA true SG11201803382XA (en) 2018-05-30

Family

ID=55130446

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803382XA SG11201803382XA (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists

Country Status (13)

Country Link
US (3) US9688660B2 (enrdf_load_stackoverflow)
EP (1) EP3368526B1 (enrdf_load_stackoverflow)
JP (1) JP6874014B2 (enrdf_load_stackoverflow)
CN (1) CN108430991B (enrdf_load_stackoverflow)
AR (1) AR106487A1 (enrdf_load_stackoverflow)
AU (1) AU2016344689A1 (enrdf_load_stackoverflow)
BR (1) BR112018008416A2 (enrdf_load_stackoverflow)
CA (1) CA3002625A1 (enrdf_load_stackoverflow)
GB (1) GB201519194D0 (enrdf_load_stackoverflow)
IL (1) IL258894A (enrdf_load_stackoverflow)
SG (1) SG11201803382XA (enrdf_load_stackoverflow)
TW (1) TW201722936A (enrdf_load_stackoverflow)
WO (1) WO2017072723A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
KR20220114613A (ko) * 2019-12-17 2022-08-17 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 저해제의 비강내 약제학적 조성물
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药(上海)有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
EA004037B1 (ru) 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR20050008790A (ko) * 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
JP2007524568A (ja) 2003-12-05 2007-08-30 ブリストル−マイヤーズ スクイブ カンパニー カルシトニン遺伝子関連ペプチドレセプターアンタゴニスト
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
CN101039718A (zh) 2004-10-14 2007-09-19 默克公司 Cgrp受体拮抗剂
JP2008517916A (ja) 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド Cgrp受容体拮抗薬
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
PE20080153A1 (es) 2006-06-08 2008-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
PL2379525T3 (pl) * 2008-12-19 2016-01-29 Centrexion Therapeutics Corp Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
GB201519194D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists

Also Published As

Publication number Publication date
CN108430991A (zh) 2018-08-21
EP3368526A1 (en) 2018-09-05
WO2017072723A1 (en) 2017-05-04
EP3368526B1 (en) 2019-12-25
IL258894A (en) 2018-06-28
BR112018008416A2 (pt) 2018-10-23
CA3002625A1 (en) 2017-05-04
JP6874014B2 (ja) 2021-05-19
CN108430991B (zh) 2021-01-05
US20170239236A1 (en) 2017-08-24
US20180153876A1 (en) 2018-06-07
US10166226B2 (en) 2019-01-01
GB201519194D0 (en) 2015-12-16
JP2018532790A (ja) 2018-11-08
US9688660B2 (en) 2017-06-27
US20170121311A1 (en) 2017-05-04
AU2016344689A1 (en) 2018-05-17
AR106487A1 (es) 2018-01-17
TW201722936A (zh) 2017-07-01
US9925178B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
RS62317B1 (sr) Trpv4 antagonisti
IL258893A (en) Cgrp receptor antagonists
IL258737A (en) Antagonists ep4
ZA201800452B (en) Cgrp receptor antagonists
IL244356B (en) Formulations for cgrp receptor antagonists
IL258894A (en) Cgrp receptor antagonists
IL267686A (en) Integrin antagonists
GB201707499D0 (en) Orexin receptor antagonists
GB201702174D0 (en) Orexin receptor antagonists
GB201507202D0 (en) Receptor tyosine kinase biomarkers
IL252903A0 (en) cgrp antagonist peptides
ZA201807767B (en) Angiotensin-1-receptor antagonists
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
ZA201704249B (en) Cgrp antagonist peptides
GB201707504D0 (en) Orexin receptor antagonists
TH1601001484A (th) สูตรผสมสำหรับ cgrp รีเซปเตอร์แอนตะกอนิสต์